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Background: Multiple sclerosis (MS) is a common disease of the central nervous system and a major
cause of disability amongst young adults. Genome-wide association studies have identi-
ﬁed many novel susceptibility loci including rs2248359. We hypothesized that genotypes of this
locus could increase the risk of MS by regulating expression of neighboring gene, CYP24A1 which
encodes the enzyme responsible for initiating degradation of 1,25-dihydroxyvitamin D3.
Methods: We investigated this hypothesis using paired gene expression and genotyping data from
three independent datasets of neurologically healthy adults of European descent. The UK Brain
Expression Consortium (UKBEC) consists of post-mortem samples across 10 brain regions originating
from 134 individuals (1231 samples total). The North American Brain Expression Consortium (NABEC)
consists of cerebellum and frontal cortex samples from 304 individuals (605 samples total). The brainThe Authors. Published by Elsevier B.V. All rights reserved.
13.08.009
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to this work.
A. Ramasamy et al.212dataset from Heinzen and colleagues consists of prefrontal cortex samples from 93 individuals.
Additionally, we used gene network analysis to analyze UKBEC expression data to understand
CYP24A1 function in human brain.
Findings: The risk allele, rs2248359-C, is strongly associated with increased expression of CYP24A1
in frontal cortex (p-value=1.45 1013), but not white matter. This association was replicated using
data from NABEC (p-value=7.2 106) and Heinzen and colleagues (p-value=1.2 104). Network
analysis shows a signiﬁcant enrichment of terms related to immune response in eight out of the 10
brain regions.
Interpretation: The known MS risk allele rs2248359-C increases CYP24A1 expression in human brain
providing a genetic link between MS and vitamin D metabolism, and predicting that the
physiologically active form of vitamin D3 is protective. Vitamin D3's involvement in MS may relate
to its immunomodulatory functions in human brain.
Funding: Medical Research Council UK; King Faisal Specialist Hospital and Research Centre, Saudi
Arabia; Intramural Research Program of the National Institute on Aging, National Institutes of
Health, USA.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is one of the most common diseases
of the central nervous system with a lifetime risk of 1:400
(Compston and Coles, 2002). It typically affects young
adults causing intermittent neurological disturbances fol-
lowed by progressive accumulation of disability. Studies of
twins, siblings and adoptees demonstrate that MS has a
signiﬁcant heritable component, contributing to an overall
familial recurrence rate of 20% (Hansen et al., 2005; Willer
et al., 2003; Compston and Coles, 2008). Consistent with
the understanding of MS primarily as an inﬂammatory
disorder of the brain and spinal cord, the most established
genetic associations with MS relate to the inheritance of the
major histocompatibility complex and in particular the DR15
and DQ6 alleles.
More recently genome-wide association studies have pro-
vided additional insights. The largest collaborative genome-
wide association study to date (Sawcer et al., 2011), involving
nearly 10,000 cases and 17,000 controls derived from European-
descent populations, highlighted a role for T cell-mediated
immune mechanisms in MS, but also identiﬁed some novel
susceptibility loci that appeared to be unrelated to the immune
system. One example is the novel risk allele rs2248359-C
(located on position 52,791,518 of chromosome 20, odds ratio
of 1.12, reported p-value=2.50 1011). This is a common
variant (risk allele frequency estimate of 60% in Europeans) and
is located less than 4 kilobases upstream of CYP24A1 in a
promoter associated region (as annotated within the Ensembl
Regulatory Build), raising the possibility that it may operate by
changing the expression of this gene, in effect making it an
Expression Quantitative Trait Locus (eQTL). However, no func-
tional evidence has been put forward to support this.
We test this hypothesis by investigating the effect of
rs2248359 on gene expression in two large and independent
brain consortiums – UK Brain Expression Consortium (UKBEC)
(Trabzuni et al., 2011; Trabzuni et al., 2012; Ramasamy et al.,
2013) and North American Brain Expression Consortium (NABEC)
(International Parkinson's Disease Genomics Consortium(IPDGC), 2011; Gibbs et al., 2010; Hernandez et al., 2012) –
as well a publicly available dataset (Heinzen et al., 2008).
2. Methods
2.1. UKBEC – tissue collection, RNA isolation and
processing of brain samples analyzed using
Affymetrix Exon 1.0 ST arrays
Brain samples were derived from 134 adult individuals of
European ancestry with no signiﬁcant neurological history or
neuropathological abnormality (determined by a consultant
neuropathologist). The samples were collected by the Medical
Research Council (MRC) Sudden Death Brain and Tissue Bank
(Millar et al., 2007), Edinburgh, UK, and the Sun Health Re-
search Institute (SHRI) Brain Donation Program (Beach et al.,
2008) an afﬁliate of Sun Health Corporation, USA. All samples
had fully informed consent for retrieval and were authorized
for ethically approved scientiﬁc investigation (Research Ethics
Committee number 10/H0716/3).
Up to 10 brain regions were sampled from each individual
resulting in a total of 1231 Affymetrix Human Exon 1.0 STarrays
(after quality control). The regions sampled were frontal cortex
(FCTX), occipital cortex (speciﬁcally Brodmann area 17, OCTX),
temporal cortex (TCTX), intralobular white matter (WHMT),
hippocampus (HIPP), thalamus (THAL), putamen (PUTM), sub-
stantia nigra (SNIG), the inferior olivary nucleus (sub-dissected
from the medulla, MEDU) and the cerebellar cortex (CRBL).
Total RNA was isolated from human post-mortem brain
tissues using the miRNeasy 96 well kit (Qiagen, UK) and
processed using the Ambions WT Expression Kit and Affymetrix
GeneChip Whole Transcript Sense Target Labeling Assay, fol-
lowed by hybridization to the Affymetrix Exon 1.0 ST Arrays
according to the manufacturers' protocols. Hybridized arrays
were scanned on an Affymetrix GeneChips Scanner 3000 7G
and visually inspected for hybridization artefacts. Further
details regarding tissue collection, sample demographics, RNA
isolation, quality control and processing have been previously
reported (Trabzuni et al., 2011).
213Genetic evidence for CYP24A1 in MS2.2. NABEC – collection, RNA isolation and
processing of brain samples analyzed using Illumina
Human HT-12 v3 expression beadchip arrays
Cerebellar and frontal cortex samples originating from 304
neuropathologically-conﬁrmed control adult individuals of
European ancestry were collected as previously described
(International Parkinson's Disease Genomics Consortium
(IPDGC), 2011; Gibbs et al., 2010; Hernandez et al., 2012).
Total RNA was extracted from dissected samples (100–200 mg)
of human post-mortem brain tissue using a glass-Teﬂon
homogenizer and 1 mLTRIzol (Invitrogen, Carlsbad, CA) accor-
ding to the manufacturers' instructions. RNA was biotinylated
and ampliﬁed using the Illuminas TotalPrep-96 RNA Ampliﬁca-
tion Kit and directly hybridized onto Human HT12v3 Expression
BeadChips (Illumina Inc., USA) in accordance with the manu-
facturer's instructions.
2.3. Brain dataset from Heinzen et al. (2008
This dataset consists of prefrontal cortex tissues from 93
adult individuals of European ancestry with no deﬁned
neuropshyciatric conditions. RNA was extracted using stan-
dard Qiagen protocols and hybridized onto Affymetrix Human
Exon 1.0 ST arrays using standard Affymetrix protocols. The
CEL ﬁles for the brain subset from this study were down-
loaded from Gene Expression Omnibus (GEO) website using
the accession GSE30483
2.4. Pre-processing of expression proﬁles
Affymetrix Human Exon 1.0 ST arrays from UKBEC were pre-
processed using Robust Multi-array Average (quantile nor-
malization, probeset summary by median polish) algorithm
in Affymetrix Power Tools 1.14.3 software (http://www.
affymetrix.com/partners_programs/ programs/developer/
tools/powertools.affx). After re-mapping the Affymetrix
probe sets onto human genome build 19 (GRCh37) as
documented in the Netaffx annotation ﬁle (HuEx-1_0-st-v2
Probeset Annotations, Release 31), we restricted analysis to
probe sets that had gene annotation and contained at least
three probes that were uniquely hybridized and did not
contain any polymorphism (Ramasamy et al., 2013). This
resulted in 14 exon-level probesets for CYP24A1 (Affymetrix
transcript ID 3910429) from which we calculated the
transcript-level expression as the 10% Winsorized mean.
We pre-processed the expression data for the brain subset
of Heinzen et al. (2008) in the same way. Prior to use in
eQTL analyses, the expression data was corrected for
gender and batch effects (date of hybridization and brain
bank or collection sites), as described previously (Trabzuni
et al., 2011).
The expression data from Illumina Human HT12v3 Expres-
sion BeadChip Arrays from NABEC were analyzed using the
Gene Expression Module 3.2.7 within Illuminas BeadStudio.
Raw intensity values for each probe were transformed using
the cubic spline normalization method and then log2
transformed for mRNA analysis. We re-mapped the annota-
tion for probes according to ReMOAT (Barbosa-Morais et al.,
2010) on the human genome build 19 and then restricted
the analysis to genes that were reliable, uniquely hybridizedand were associated with gene descriptions. The probe for
CYP24A1 on this array is ILMN_1685663. Prior to use in eQTL
analyses, the expression data was corrected for gender, age,
PMI and batch effects (hybridization batch effects and brain
bank), as described previously (Gibbs et al., 2010).
2.5. DNA extraction, genotyping of rs2248359
and imputation
Genomic DNA for individuals from UKBEC was extracted from
sub-dissected samples (100–200 mg) of human post-mortem
brain tissue using Gentra Puregene Kit (Qiagen, UK). Samples
from every individual were run on two different genotype
chips: the Illumina Inﬁnium Omni1-Quad BeadChip and the
ImmunoChip, a custom genotyping array designed for the ﬁne-
mapping of auto-immune disorders (International Parkinson's
Disease Genomics Consortium (IPDGC), 2011; Nalls et al.,
2011). The BeadChips were scanned using an iScan (Illumina,
USA) with an AutoLoader (Illumina, USA). GenomeStudio v.1.8.
X (Illumina, USA) was used for analyzing the data and
generating SNP calls. Three individuals suspected of being of
non-European ancestry were identiﬁed in UKBEC (134 remain-
ing) using principal components projection and excluded from
analysis. The DNA for individuals from NABEC were extracted
and analyzed in similarly using the Illumina Inﬁnium Human-
Hap550 v3 (Illumina, USA). The DNA for Heinzen et al. (2008)
was extracted and analyzed using standard Qiagen protocols
using the Illumina Human Hap550K chips.
The risk SNP rs2248359 was genotyped in all three
datasets. To explore the presence of other eQTL signals,
we can use imputation to infer additional untyped SNPs by
using the identiﬁed linkage disequilibrium information
between typed and untyped SNPs from reference panels that
have a vastly more comprehensive set of SNPs. We used the
software MaCH (Li et al., 2010; Li et al., 2009) and minimac
(http://genome.sph.umich.edu/wiki/Minimac) with the 1000
Genomes (March 2012 release) as reference panel to impute
the UKBEC and NABEC datasets. We used the resulting SNPs
with good post-imputation quality (r240.50) and minor allele
frequency of at least 5% in subsequent analyses.
2.6. Statistical analysis for identifying eQTL
The association between gene expression residuals and SNP
was tested using a linear regression model in R software
(http://www.r-project.org/) assuming an additive genetic
model for genotypes. Unless stated otherwise, the reported
p-values are nominal p-values.2.7. Weighted Gene Co-expressed Network
Analysis (WGCNA) of the UKBEC gene expression
dataset
Analysis of co-expression of genes is particularly sensitive to
the presence of outlier samples. Therefore, we ﬁrst applied
rigorous quality control procedures on the UKBEC samples
from the MRC Sudden Death Brain and Tissue Bank to ensure
the highest possible level of quality. Outliers were identiﬁed
by repeated visual inspection of the hierarchical clustering
A. Ramasamy et al.214of samples with Euclidean distance and the inter-array
correlation metric. We also restricted to 15,409 transcripts
(measured as 10% windsorized mean) that passed the
detection above background criteria (p-valueo0.001 in at
least 50% of samples in at least one brain region), had a
coefﬁcient of variation 45% and at least one expression
value exceeding ﬁve in at least one brain region (Forabosco
et al., 2013).
The WGCNA network (Langfelder and Horvath, 2008) was
constructed for each tissue separately using a signed network
with power (Beta) of 12 to achieve a scale-free topology. A
dissimilarity matrix based on Topological Overlap Measure
(TOM), a pairwise measure of node similarity (i.e. how the
neighbors of a gene are to the neighbors of another gene)
was used to identify gene modules (i.e. densely intercon-
nected and co-expressed genes) which has been shown to
placing functionally related genes into groups.
Module preservation statistics calculate how well a
module from one tissue (reference data) is reproducible
(or preserved) in another tissue (test data). To construct a
statistical measure of preservation, one may use a simple
cross-tabulation analysis of module memberships and
related Fisher exact test p-value, or use a more reﬁned
preservation statistics that do not use the module assign-
ment in the test data (so called network-based statistics).
Network-based statistics assess whether the modules fea-
tures deﬁned in a reference data are preserved in a test
dataset. Here we report the Z summary statistic that
aggregates different preservation statistics (Langfelder
et al., 2011), and assess both whether module nodes remain
highly connected in the test network (quantify density), and
compares the connectivity pattern between nodes in the
reference network to test network (quantify connectivity
pattern). In order to determine whether the Z summary is
higher than expected by chance, we used a permutation
test procedure implemented in a WGCNA function, which
randomly permutes the module assignment in the test data,
and calculates the mean and variance of the preservation
statistic under the null hypothesis of no relationship
between the module assignments in reference and test
data. Then, by standardizing each observed preservation
statistic with regard to the mean and variance, we use the
thresholds proposed by (Langfelder et al., 2011): Zsummary
o2 implies no evidence for module preservation, 2
oZsummaryo10 implies weak to moderate evidence, and
Zsummary 410 implies strong evidence for module
preservation.2.8. Gene set enrichment analysis with DAVID
To evaluate the biological and functional relevance of co-
expressed genes within the CYP24A1-containing modules,
we used DAVID v6.7 (http://david.abcc.ncifcrf.gov/), the
database for annotation, visualization and integrated dis
covery (Huang da et al., 2009). We examined the over
-representation (i.e. enrichment) of Gene Ontology (GO)
terms amongst the genes within each module by comparing
numbers of signiﬁcant genes annotated within a given
biological category as compared with chance.3. Results
3.1. Distribution of CYP24A1 expression across
the human brain and evidence for regulation by
rs2248359
To investigate the impact of the MS risk SNP rs2248359 on
gene expression in human brain we used paired gene
expression and genotyping data generated by UKBEC
(Trabzuni et al., 2011; Trabzuni et al., 2012; Ramasamy
et al., 2013). This dataset is based on samples originating
from 134 individuals of European descent. In all cases there
was no history of a neurological disorder and control status
was conﬁrmed by histology with assessment by a neuro-
pathologist. The individuals sampled had a mean age at
death of 59 years old (range 16–102), were mostly men
(74.5%) and the main cause of death was ischemic heart
disease (44.7%). For each individual, up to 10 anatomical
brain regions were sampled (for a total of 1231 arrays) to
provide genome-wide expression data, including information
on CYP24A1 expression. The brain regions analyzed includes
those commonly affected in MS, namely subcortical white
matter.
We demonstrate widespread expression of CYP24A1 mRNA
in the human brain (Fig. 1A, Supplementary Fig. 1A). However,
when we stratify mRNA levels by rs2248359 genotypes, we ﬁnd
very strong evidence for the association between the risk
allele C and increased expression of CYP24A1. This association
is evident in frontal cortex (p-value=1.45 1013) and
temporal cortex (p-value=9.93 106), but not in subcortical
white matter (Fig. 1B) or any other regions in the UKBEC
dataset (Supplementary Fig. 1B). A mixed model approach
with brain regions and individuals as random effects covariates
showed signiﬁcant heterogeneity (p=0.001) between the
brain regions.
Similarly, we ﬁnd a signiﬁcant association between rs2248359
and CYP241 expression in frontal cortex (p-value=7.2 106;
Fig. 1B) but not cerebellum in the NABEC dataset (Fig. 1B).
Finally, Heinzen et al. (2008 dataset also shows an association in
the prefrontal cortex samples (p-value=1.2 104, Fig. 1B).
The direction of association was consistent across all three
datasets and there was no evidence for associations with any
other neighboring genes.
3.2. Reﬁning eQTL signals in the genomic region
We investigated the genomic region around rs2248359 for
other SNPs capable of regulating CYP24A1 expression in
frontal cortex by imputing the genotype data for UKBEC and
NABEC. We considered all SNPs within 1 Mb of the transcrip-
tion start and stop site for this gene (Fig. 2). This analysis
conﬁrms that there is only one eQTL signal in this region for
each dataset. In the UKBEC dataset, the best signal was
indeed the risk variant under investigation (rs2248359 which
is shown as a purple circle in Fig. 2A). In the NABEC dataset,
the best signal was conferred by rs2104134 (Fig. 2B, red
circle) which is located 2,932 bases upstream of the risk
variant rs2248359 and in high linkage disequilibrium with it
(haplotype r2=0.91). However, we note that rs2104134 is
imputed while rs2248359 is genotyped and the difference in
statistical signiﬁcance is marginal (p-value of 3.9 106 vs.
Fig. 1 Regional and stratiﬁed plot. (A) Boxplot showing the distribution of mRNA levels across the three datasets (selected
tissues from UKBEC). Whiskers extend from the box to 1.5 times the inter-quartile range. (B) mRNA levels stratiﬁed by the
genotypes of the MS risk SNP rs2248359 (selected tissues from UKBEC). The eQTL p-values are given on the last
x-axis.
215Genetic evidence for CYP24A1 in MS7.2 106). Even though we did not impute Heinzen et al.
(2008) dataset, we can conﬁrm that the eQTL with rs22
48359 was again the most signiﬁcant signal amongst geno-
typed SNPs.
3.3. Insights into the function of CYP24A1 in
human brain using network analysis
We investigated the role of CYP24A1 using Weighted Gene Co-
Expression Network Analysis (WGCNA) to analyze human brain
expression data from UKBEC (Forabosco et al., 2013). This
approach groups genes into modules in an unsupervised
manner (Langfelder and Horvath 2008) and has been shown
to be extremely useful in the identiﬁcation of modules of
biologically related genes that are co-expressed (Rosen et al.,
2011; Oldham et al., 2008). Using this approach we identiﬁed
a CYP24A1-containing module of genes in all 10 of the brain
regions analyzed. This module was large in all cases (average
number of genes=4300) and was well preserved across the
brain (Z summary preservation values 420 across all pairwise
tissues, Supplementary Fig. 2). Using Module Membership
(MM), as deﬁned by how well the expression pattern of each
gene within a module correlates with the ﬁrst principal
component of gene expression for that module, we assessed
the extent to which CYP24A1 “belongs” to each module. The
MM for CYP24A1 was above the median in nine out of 10 brain
regions (minimum=47th quantile, maximum=68th), indicat-
ing strong membership.
To evaluate the biological and functional relevance of
genes within the CYP24A1-containing modules we used Gene
Ontology (GO) enrichment analysis. Focusing on GO terms
relating to biological processes, this analysis demonstrateda signiﬁcant over-representation of genes annotated to the
“immune response” term (minimum Bonferroni-corrected
p-value=1.80 1011, Table 1) within the CYP24A1-con-
taining modules in eight of the 10 brain regions analyzed,
the exceptions being temporal cortex and white matter. In
fact, “immune response” was the most signiﬁcant term in
this category on the basis of corrected p-values. In keeping
with this ﬁnding similar analyses focused on the enrichment
of canonical gene sets deﬁned by the Kyoto Encyclopedia of
Genes and Genomes (KEGG) and relating to known pathways
identiﬁed the cytokine-cytokine receptor interaction path-
way in eight out of 10 brain regions (minimum Bonferroni-
corrected p-value=5.45 105).
4. Discussion
In this paper, we used three independent post-mortem
human brain expression datasets to show that the risk allele
C of a known MS disease SNP rs2248359 is strongly associated
with increased expression of CYP24A1. The increase in
expression could be a direct effect of the risk SNP or could
be an effect of a SNP in linkage disequilibrium with this SNP.
However, the SNP identiﬁed is in fact located within a
genomic region predicted by ENCODE to be a promoter
based on a range of experiments (DNAse I hypersensitivity
site identiﬁcation amongst others) performed in H1ESC and
HepG2 cells. We would therefore predict that the SNP
changes the efﬁciency of the CYP24A1 promoter resulting
in changes in transcriptional rate and mRNA levels.
We note that in UKBEC, rs2248359 had the greatest impact
on CYP24A1 expression in frontal cortex and temporal cortex
despite the gene being widely expressed in human brain and MS
Fig. 2 Reﬁning eQTL signals in the genomic region. Regional association plot illustrating the expression quantitative trait loci
(eQTL) around the gene CYP24A1 in frontal cortex for (A) UKBEC dataset and (B) NABEC dataset. The MS risk SNP rs2248359 is shown
in purple and the LD measures are with respect to this SNP.
A. Ramasamy et al.216being classically characterized as a disease of white matter.
Although this is surprising, this ﬁnding is in keeping with the
increasing recognition of the extensive involvement of gray
matter in MS pathology (Geurts et al., 2012). Demyelination in
the gray matter commonly occurs and in fact gray matter
pathology is more closely associated with neurological and
neuropsychological disability than white matter lesions or
whole brain atrophy (Geurts et al., 2012).
Given that CYP24A1 encodes the enzyme responsible for
initiating the degradation of 1,25-dihydroxyvitamin D3 (the
physiologically active form of vitamin D3) we suggest that the
observation of an eQTL provides genetic evidence for apathogenic role for low levels of 1,25-dihydroxyvitamin D3 in
MS. Previous genetic evidence for such a link has been
inconsistent. One study (Ramagopalan et al., 2011) reported
that rare, loss-of-function variation in CYP27B1 (the gene
encoding 25-hydroxyvitamin D 1α hydroxylase, which converts
25 hydroxyvitamin D(25[OH]D) into its active form) increased
MS risk, but two subsequent studies (Barizzone et al., 2013;
Ban et al., 2013) failed to replicate this ﬁnding. However, the
link between MS and vitamin D is supported by epidemiological
evidence (Simon et al., 2012). In fact, the possibility that
vitamin D deﬁciency may be a risk factor for multiple sclerosis
was proposed more than 30 years ago, primarily to explain the
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217Genetic evidence for CYP24A1 in MSobservation of a latitude gradient in MS prevalence (Simon
et al., 2012). This has led to further studies demonstrating
that low vitamin D levels are associated with a high risk of
developing MS and vitamin D supplementation reduces the risk
(Simon et al., 2012).
With regard to how vitamin D might exert a protective
effect on MS risk, there is a growing body of work to suggest
that vitamin D has immunomodulatory functions which could
be relevant to pathogenesis (Simon et al., 2012; Ascherio
et al., 2012). This hypothesis is supported by the results of
gene expression network analysis on human brain tissue and in
particular the enrichment of immune-related genes within the
CYP24A1-containing gene modules. It is noteworthy that this
enrichment was not observed in the CYP24A1-containing gene
module in white matter, raising the possibility that there may
be some differences in the underlying pathogenic processes in
MS in white versus gray matter.
Thus, in summary we demonstrate that the known MS risk
SNP rs2248359 regulates CYP24A1 expression in human brain
providing a genetic link between MS and vitamin D meta-
bolism. We also provide evidence in support of the hypoth-
esis that the protective effects of vitamin D are related to
its immunomodulatory functions in human brain. Further
research into this proposed mechanism is warranted and
the use of dietary supplementation should, perhaps, be
considered.
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